Erlotinib and Irinotecan in Treating Patients With Advanced Solid Tumors

This study is ongoing, but not recruiting participants.

Study NCT00045201 Information provided by National Cancer Institute (NCI)

First Received: September 6, 2002 Last Updated: May 20, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Publications:

Pitot H, Reid J, Goetz M, et al.: UGT1A1*28 genotype determines the maximally tolerated dose (MTD) of OSI-774 and CPT-11 in patients with advanced solid tumors. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-B86, 2007.